GEN Exclusives

More »

GEN News Highlights

More »
Nov 15, 2010

Agensys Taps BioWa Technology for Cancer Antibody Discovery

  • BioWa is providing Agensys with access to its Potelligent Technology platform for the purpose of identifying antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC). Under the terms of the license agreement Agensys gains nonexclusive rights to conduct research using Potelligent for an undisclosed number of targets. In return BioWa will receive annual research license fees.

    The Potelligent Technology has harnessed the ability to create 100% fucose-free mAbs, thereby enhancing ADCC, the critical factor in antitumor activity, according to BioWa. The amount of fucose in the carbohydrate structure of an antibody is reduced by using a proprietary fucosyltransferase-knockout CHO cell line for production, which improves potency and efficacy of antibody therapeutics.

    "Agensys’ world-class R&D organization and breath of targets in solid tumors will greatly extend the benefits of the Potelligent Technology,” says Masamichi Koike, Ph.D., BioWa's president and CEO.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?